Synthaverse stock costs EUR 0.64 as H1 revenue rises to PLN 26.46 million

Published on 10/15/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue reached PLN 26.46 million, up 34.20 percent year over year. Synthaverse stock costs EUR 0.64 on October 15, 2026, while EBITDA reached PLN 5.42 million.

Operating figures and reporting date

First-half revenue reached PLN 26.46 million on September 30, 2026.
First-half EBITDA reached PLN 5.42 million, up 142.00 percent year over year.
Synthaverse stock traded at EUR 0.64 at 1:46 p.m. CEST at Lang & Schwarz on October 15, 2026.

Biomed Lublin, PLBMDLB00018, Illustration mit AI erstellt.

Synthaverse stock (ISIN PLBMDLB00018) costs EUR 0.64 at Lang & Schwarz on October 15, 2026, while the pharmaceutical company advances after first-half revenue reached PLN 26.46 million. The results published on September 30, 2026 showed stronger operating performance but a deeper net loss, according to BiznesRadar.

Revenue growth meets refinancing work

Revenue in the first half of 2026 increased 34.20 percent from PLN 19.71 million in the first half of 2025 to PLN 26.46 million. The same report showed a net loss of PLN 6.37 million, compared with a PLN 5.31 million loss a year earlier, keeping profitability as the main counterweight to sales growth.

Operating cash flow reached PLN 6.80 million in the first half of 2026, while management continued work on debt optimization and refinancing. The company also reported first-half sales of PLN 8.98 million for Distreptaza and PLN 14.50 million for Onko BCG, according to BiznesRadar.

What does EBITDA growth mean?

EBITDA rose to PLN 5.42 million from PLN 2.24 million a year earlier, an increase of 142.00 percent. That operating improvement was not enough to offset depreciation and finance costs, which left the company with a negative bottom line despite higher sales.

Stock context on October 15

Synthaverse operates in healthcare biotechnology and makes pharmaceutical products, medical devices and laboratory reagents. Its market capitalization stood at PLN 214.4 million on October 15, 2026, while the next reported earnings date is December 2, 2026, according to Investing.com.

For investors, the central question is whether operating growth can translate into net earnings after financing costs. The September 30, 2026 report provides a mixed picture: revenue and EBITDA advanced, while the net loss widened.

The stock was trading at EUR 0.64 at Lang & Schwarz on October 15, 2026 at 1:46 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Synthaverse stock.